Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...

NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...

Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...

Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...

A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.